NeuroVive Pharmaceutical AB Propriété du management
Quel est le Propriété du management de NeuroVive Pharmaceutical AB?
Le Propriété du management de NeuroVive Pharmaceutical AB est 17.55%
Quelle est la définition de Propriété du management?
La propriété d'un initié est calculée en divisant le nombre total d'actions possédées par des initiés (actionnaires détenant plus de 5% de la société ou un dirigeant ou un administrateur de la société) par le nombre total d'actions en circulation.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Propriété du management des entreprises dans Miscellaneous secteur sur LSE par rapport à NeuroVive Pharmaceutical AB
Que fait NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Entreprises avec propriété du management similaire à NeuroVive Pharmaceutical AB
- Meteorite Capital a Propriété du management de 17.54%
- Distribution Finance Capital plc a Propriété du management de 17.54%
- Electro Optic Systems a Propriété du management de 17.55%
- Kuya Silver a Propriété du management de 17.55%
- Medgold Resources a Propriété du management de 17.55%
- HMN a Propriété du management de 17.55%
- NeuroVive Pharmaceutical AB a Propriété du management de 17.55%
- Ponce Inc a Propriété du management de 17.56%
- Valneva SE a Propriété du management de 17.57%
- Sichuan Expressway a Propriété du management de 17.57%
- Valneva SE a Propriété du management de 17.57%
- China Merchants Bank Co a Propriété du management de 17.57%
- Synaptogenix Inc a Propriété du management de 17.57%